^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lunresertib (Debio2513)

    i
    Other names: Debio2513, RP-6306, RP 6306, Manchester, RP6306, Debio-2513
    Company:
    Debiopharm, XenoTherapeutics
    Drug class:
    PKMYT1 inhibitor
    Related drugs:
    Apply
    RP-6306 in Patients With Advanced Cancer (NCT05605509)
    Phase 2
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/24/2023
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    HER-2 • KRAS • TP53 • CCNE1 • UGT1A1
    |
    TP53 mutation • KRAS mutation • HER-2 amplification • RAS mutation • CCNE1 amplification • UGT1A1*28 • UGT1A1*1*1
    |
    Herceptin (trastuzumab) • gemcitabine • 5-fluorouracil • irinotecan • leucovorin calcium • lunresertib (Debio2513)
    Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (GyneRep) (NCT06107868)
    Phase 1
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    03/22/2024
    Initiation :
    03/20/2024
    Primary completion :
    12/04/2026
    Completion :
    12/04/2026
    TP53
    |
    TP53 mutation
    |
    carboplatin • paclitaxel • lunresertib (Debio2513)